Orgenesis Performance
| ORGSDelisted Stock | USD 1.22 0.31 20.26% |
The company holds a Beta of 4.59, which implies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Orgenesis will likely underperform. At this point, Orgenesis has a negative expected return of -3.96%. Please make sure to check Orgenesis' value at risk, as well as the relationship between the daily balance of power and price action indicator , to decide if Orgenesis performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Orgenesis has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's technical and fundamental indicators remain comparatively stable which may send shares a bit higher in January 2025. The newest uproar may also be a sign of mid-term up-swing for the firm private investors. ...more
| Begin Period Cash Flow | 6.4 M |
Orgenesis |
Orgenesis Relative Risk vs. Return Landscape
If you would invest 390.00 in Orgenesis on September 23, 2024 and sell it today you would lose (268.00) from holding Orgenesis or give up 68.72% of portfolio value over 90 days. Orgenesis is currently does not generate positive expected returns and assumes 13.7165% risk (volatility on return distribution) over the 90 days horizon. In different words, most equities are less risky than Orgenesis, and most traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Orgenesis Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Orgenesis' investment risk. Standard deviation is the most common way to measure market volatility of otc stocks, such as Orgenesis, and traders can use it to determine the average amount a Orgenesis' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.289
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | ORGS |
Estimated Market Risk
| 13.72 actual daily | 96 96% of assets are less volatile |
Expected Return
| -3.96 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.29 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Orgenesis is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Orgenesis by adding Orgenesis to a well-diversified portfolio.
Orgenesis Fundamentals Growth
Orgenesis OTC Stock prices reflect investors' perceptions of the future prospects and financial health of Orgenesis, and Orgenesis fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Orgenesis OTC Stock performance.
| Return On Equity | -7.27 | ||||
| Return On Asset | -0.3 | ||||
| Operating Margin | (16.54) % | ||||
| Current Valuation | 23.01 M | ||||
| Shares Outstanding | 4.77 M | ||||
| Price To Earning | 7.52 X | ||||
| Price To Book | 1.26 X | ||||
| Price To Sales | 15.21 X | ||||
| Revenue | 530 K | ||||
| EBITDA | (54.07 M) | ||||
| Cash And Equivalents | 2.3 M | ||||
| Cash Per Share | 0.09 X | ||||
| Total Debt | 22.62 M | ||||
| Debt To Equity | 0.64 % | ||||
| Book Value Per Share | (3.30) X | ||||
| Cash Flow From Operations | (14.84 M) | ||||
| Earnings Per Share | (8.00) X | ||||
| Total Asset | 14.55 M | ||||
| Retained Earnings | (176.62 M) | ||||
| Current Asset | 5.29 M | ||||
| Current Liabilities | 14.92 M | ||||
About Orgenesis Performance
Assessing Orgenesis' fundamental ratios provides investors with valuable insights into Orgenesis' financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Orgenesis is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
Orgenesis Inc., a biotech company, focusing on cell and gene therapies worldwide. Orgenesis Inc. was incorporated in 2008 and is based in Germantown, Maryland. Orgenesis operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 151 people.Things to note about Orgenesis performance evaluation
Checking the ongoing alerts about Orgenesis for important developments is a great way to find new opportunities for your next move. OTC Stock alerts and notifications screener for Orgenesis help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Orgenesis is not yet fully synchronised with the market data | |
| Orgenesis generated a negative expected return over the last 90 days | |
| Orgenesis has high historical volatility and very poor performance | |
| Orgenesis may become a speculative penny stock | |
| Orgenesis has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 530 K. Net Loss for the year was (64.92 M) with profit before overhead, payroll, taxes, and interest of 36.02 M. | |
| Orgenesis currently holds about 2.3 M in cash with (14.84 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.09. | |
| Roughly 21.0% of the company outstanding shares are owned by corporate insiders |
- Analyzing Orgenesis' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Orgenesis' stock is overvalued or undervalued compared to its peers.
- Examining Orgenesis' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Orgenesis' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Orgenesis' management team can help you assess the OTC Stock's leadership.
- Pay attention to analyst opinions and ratings of Orgenesis' otc stock. These opinions can provide insight into Orgenesis' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be closely tied with the direction of predictive economic indicators such as various price indices. Note that the Orgenesis information on this page should be used as a complementary analysis to other Orgenesis' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Diagnostics module to use generated alerts and portfolio events aggregator to diagnose current holdings.
Other Consideration for investing in Orgenesis OTC Stock
If you are still planning to invest in Orgenesis check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Orgenesis' history and understand the potential risks before investing.
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities |